Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Resverlogix Corp RVXCF

Primary Symbol: T.RVX

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the... see more

Add To Watchlist

Recent & Breaking News (TSX:RVX)

Resverlogix Announces Private Placement

GlobeNewswire August 14, 2020

Resverlogix Announces Publication on Apabetalone in Cardiovascular Therapeutics

GlobeNewswire August 4, 2020

Zenith Epigenetics Advances ZEN-3694 in Multiple Cancer Programs

GlobeNewswire July 29, 2020

Resverlogix Announces Extension of its Filing Calendar Based on Continuous Disclosure Exemption

GlobeNewswire July 28, 2020

Resverlogix Secures One-Year Extension of Maturity Date of Debenture

GlobeNewswire July 22, 2020

Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study

GlobeNewswire June 22, 2020

Zenith Announces Corporate Update Conference Call & Webcast on June 18, 2020 and US$5 Million Equity Investment

GlobeNewswire June 16, 2020

Resverlogix Announces Key BETonMACE Renal Data from Plenary Session Presentation at ERA-EDTA Virtual Congress

GlobeNewswire June 9, 2020

Resverlogix Announces Corporate Update Conference Call & Webcast on June 10, 2020 and Upcoming Presentation at the 57th ERA-EDTA Virtual Congress on June 9, 2020

GlobeNewswire June 5, 2020

Resverlogix Plans COVID-19 Clinical Trial Program Launch

GlobeNewswire June 1, 2020

Resverlogix Announces Participation at the American College of Cardiology Scientific Sessions together with the World Congress of Cardiology Virtual

GlobeNewswire March 31, 2020

Resverlogix Announces Publication of Key Apabetalone Study BETonMACE in the Journal of the American Medical Association

GlobeNewswire March 30, 2020

Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication

GlobeNewswire March 24, 2020

The Top Healthcare Bullboards: Jan - Mar 2020

Stockhouse Editorial March 23, 2020

Resverlogix Invites Collaborations for use of Apabetalone in Trials and Studies to Combat the Spread of COVID-19 Based on New Research

GlobeNewswire March 23, 2020

Resverlogix Receives US FDA Breakthrough Therapy Designation for Apabetalone

GlobeNewswire February 3, 2020

CORRECTION: Resverlogix Confirms a Significant Corporate Advancement Establishing Apabetalone as a Potential Blockbuster Combination Drug in High-risk Diabetes Patients with CVD

GlobeNewswire January 13, 2020

Resverlogix Confirms a Significant Corporate Advancement Establishing Apabetalone as a Potential Blockbuster Combination Drug in High-risk Diabetes Patients with CVD

GlobeNewswire January 13, 2020

Resverlogix Appoints Dicky To to its Board of Directors

GlobeNewswire December 20, 2019

Zenith Epigenetics Announces Clinical Advancement of ZEN-3694

GlobeNewswire December 19, 2019

Featured News Links

Positive PEA for Uranium-Vanadium Deposit After-tax NPV 8%: $227.7 million with IRR: 38.9%

Fokus Mining Welcomes Luc Gervais To Its Board Of Directors

The Increasing Investments by the Defense and Military Sectors is Driving the Demand for Helium